To integrate experimental and clinical evidence, we next compared the functional pathways emerging from LGALS3 knockout in the YAPC pancreatic cancer cell line with those identified through co-expression analysis of LGALS3 in TCGA-PAAD tumors, aiming to define convergent biological programs associated with galectin-3 in pancreatic cancer (Figure 4). The gene discussed is LGALS3; the disease is pancreatic neoplasm.